Working with the Global Drug Facility

Slides:



Advertisements
Similar presentations
Quality Assurance Processes for TB Drugs. GDF Quality Assurance Processes.
Advertisements

Vertical versus Decentralized TB Pharmaceutical Management
PROCUREMENT SUPPORT SERVICES Voluntary Pooled Procurement & Capacity Building Services Technical Briefing Seminar November 18, 2009.
Technical cooperation with countries Technical Cooperation for essential drugs and traditional medicines September 2005.
THE INTERNATIONAL DRUG PURCHASE FACILITY-UNITAID Michel D. Kazatchkine, Ministère des Affaires Etrangères, France.
The Roadmap to Successful Xpert Implementation - 37 steps -
5 th Consultative Stakeholder meeting UN Prequalification of Diagnostics, Medicines and Vaccines 11 Feb 2010 Achievements and Impacts of prequalification.
Key elements to develop a national strategic plan for TB control Malgosia Grzemska Stop TB Department WHO, Geneva, Switzerland EURO/TBTEAM Regional Workshop.
DFG Workshop - Middlesbrough Driving Change Shirley Janes Housing Improvement Manager.
Ukraine Grant Making Mission Debrief. Purpose of the mission Agree on reinvestment of savings; Clarify TRP recommendations; Agree on implementation arrangements;
This teaching material has been made freely available by the KEMRI-Wellcome Trust (Kilifi, Kenya). You can freely download, adapt, and distribute this.
IPC meeting June 2014 Dr Joelle DAVIAUD, Quality Assurance Specialist Model Quality Assurance System for procurement agencies.
WHO Workshop on Prequalification of Medicines Programme, Abu Dhabi, October, 2010 Khaled Sultan GDF Regional Support officer, STB/ EMRO QUALITY ASSURANCE.
Procurement Support Services WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, October 29 th - November 2 nd 2012 Mariatou Tala Jallow.
Access to HIV/AIDS, Tuberculosis and Malaria Medicines. WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies. Geneva, 18 – 22 September.
USAID TB Technical Assistance Model June 19, 2014.
TBS Meeting Geneva, November 2011 Global Fund Policies and Reporting on Procurement of Health Products WHO/UNICEF Technical Briefing Seminar on Essential.
African Business Leaders on Health GBC Conference on TB, HIV-TB Co-infection & Global Fund Partnership Johannesburg, October 2010 Technical Assistance.
PROCUREMENT SUPPORT SERVICE WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November 1 st -5 th 2010 Mariatou Tala Jallow, Manager,
Improving Access for Quality-Assured TB Medicines and Diagnostics Dr Kaspars Lunte Team Leader Sourcing and Special Projects, GDF Copenhagen, IPC Meeting.
Access to and Management of 2 nd Line Drugs Challenges Summarized at 6 th Meeting, STB Working Group of MDR-TB September Tbilisi.
Wilbert Bannenberg SARPAM
AMFm Overview and Case Management Observations RBM Case Management Working Group (CMWG)
GLOBAL DRUG FACILITY Improving country access to anti-TB medicines Andrea de Lucia, GDF Team Leader 1 st line Country Support WHO/UNICEF Technical Briefing.
“The causes of Anti-TB medicines shortages in EMR countries and how to avoid them in the future” Khaled Sultan Drug Management Technical Officer, STOP.
QUALITY REPRODUCTIVE HEALTH SUPPLIES Dr Hans V. Hogerzeil Director Essential Medicines & Pharmaceutical Policies.
Access to Medicines- OHCHR Geneva, October 11, 2010 Access to Medicines- the Global Fund Experience Pharmaceutical Management Unit October 11, 2010.
Good Procurement Practices in National TB Programs
RHSC Meeting Kampala, May 2010 Quality for Medicines The Global Fund approach Sophie Logez Manager, QA and Data Quality Pharmaceutical Management.
Real-World Challenges of M&E. Objectives Outline the “real-world” challenges of conducting program monitoring and evaluation. Identify practical and feasible.
TFM Progress Update Malaria Tobgyel, Dy. Chief Programme Officer Vector-borne Disease Control 31st CCM meting, 28th August, 2015.
Lucile de Comarmond Chief Pharmacist Workshop on Impact of TRIPS/IP on Access to Medicine September 2014.
Overview of the Global Fund Procurement and Supply Management Issues Workshop for LAC Consultants th July 2009 Pharmaceutical Management Advisory.
Overview of 2000 Survey of TB Drug Supply Experiences in Low- and Middle-Income WHO Member States Diana Weil Senior Public Health Specialist World Bank/United.
Quality Assurance for pharmaceutical products in international procurement Approach of major donors and procurers Core presentation prepared by Sophie.
M ODULE 5 PART 1: Introduction to Consolidation of Pharmaceutical and Health Product Management (PHPM) in the SSF Context GLOBAL FUND GRANT CONSOLIDATION.
AMC Governance and Institutional Support. Objectives Build on existing capacity Ensure appropriate independence and credibility through transparency,
From 3by5 to Universal Access to HIV/AIDS Treatment: AMDS Technical Briefing Seminar for Consultants on Procurement and Supply Management for HIV, TB and.
1 SUPPLY DIVISION Procurement and Supply Management Technical Assistance.
Global Fund Assessments Part II: Understanding Assessment Results Geneva – December 2005.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
1 SUPPLY DIVISION Procurement and Supply Management Technical Assistance.
TBS Meeting Geneva, November 2010 Procurement and Supply Management Policies WHO/UNICEF Technical Briefing Seminar on Essential Medicines Policies, November.
Drug Management of Second-line anti-TB drugs through the Green Light Committee mechanism for programmes funded by the Global Fund to Fight Against AIDS,
1 Global Drug Facility presentation IPC meeting 10 December 2015 Magali Babaley Procurement, supply and country support manager.
Improving Access for Quality-Assured TB Medicines and Diagnostics Medicines and Diagnostics Improving Access for Quality-Assured TB Medicines and Diagnostics.
Supply Chain Management of Second Line Drugs: Russian Example Dr Vadim V. Testov Central TB Research Institute, Moscow, the Russian Federation.
Improving Access for Quality-Assured TB Medicines and Diagnostics Medicines and Diagnostics Improving Access for Quality-Assured TB Medicines and Diagnostics.
Ensuring quality of medicines procured with Global Fund resources HIV AIDS conference Satellite on Essential Medicines for HIV AIDS Mexico 6 August 2008.
PROCUREMENT SUPPORT SERVICE
Procurement and Supply Management Policies
Procurement and Supply Management for iCCM – common challenges
PSM Technical Briefing Seminar: Day One report
Global Drug Facility An innovative approach to supplying anti-TB drugs
Increased access to quality TB drugs
Access to Medicines for HIV/AIDS, Tuberculosis and Malaria.
Review of integrated PSM resources and tools and introduction to group work Upjeet Chandan ICCM FTT 17th February 2016.
Health Supply Chain Management: Session 6: Facilities, Staffing and Procurement Ghana Nursing Schools.
Dr Pierre-Yves Norval WHO Stop TB Department
Impact of Using Fixed Dose Combinations (FDCs) versus
Emergency Supply Chain Response Quick Guide
Access to HIV/AIDS Medicines The 3x5 strategy
Consolidated Technical Support Plan for AIDS
Vietnam Investment and Finance for TB
Global Drug Facility: Providing Access to Medicines and Commodities for Tuberculosis Thomas Moore Manager GDF Geneva, 19 November 2009.
5th DEWG meeting Conclusions
WHO Global HIV/AIDS Staff Meeting
Cost Containment Working Group Board Update
Prequalification Programme of Medicines (PQP): Introductory messages
Title : Quality data for efficient management - lessons from the UNRWA Health Procurement Strengthening Project   Abstract: Introduction :UNRWA has been.
Presentation transcript:

Working with the Global Drug Facility Andrea de Lucia 30 October 2012 TBS

Global Drug Facility (11 professional staff, 3 assistants in HQ) Thomas Moore, ad interim Team Leader 14 October 2019 GDF Team Leader Office T. Cordier-Lasalle, Principal Officer P. Marroquin Lerga, Quality Assurance H. Castel, Technical Officer/FIN T. Dansie Assistant A. de Lucia Country Support Team Leader & Francophone AFRO TO J. Lashley, Assistant J. Loeber 1st line Procurement Team Leader E. Mochinova, TO A. Kasi-Nsubuga, TO K. Lunte 2nd line Procurement Team Leader A. Garcia Montes, PO V. Bruniquel, Assistant Regional GDF Staff A. Jafarov (HQ/EUR) VACANT (EMRO) N. Mouzafarova (EURO) VACANT (SEARO) VACANT (AFRO – 3 RSOs) E.Thanaraj (GDF India) 14/10/2019

GDF Model Client Stop TB Partnership/ Global Drug Facility Procurement Agents Manufactures GDF sits in the Stop TB partnership GDF does not conduct procurement itself, but contracts with procurement agents. Procurement agents contract with manufactures, quality control agencies and freight forwarders. GDF acts in a coordinating role between clients and the procurement agents. Quality Control Freight Forwarders

GDF Expansion since 2001 MDR scale-up Paediatric grants FLD grants FDL DP 2nd line DP Diagnostic kits Expand TB GeneXpert 2001 2004 2005 2006 2007 2008 2010 2011 Strategic Revolving Stockpile GDF has expanded its product line since 2001.

Trends in GDF Procurement GDF Business volume has increased 4 fold since 2007. USD 155 million in procurement was conducted in 2011, of which USD 103 million in direct procurement services, and USD 51 million in grant services.

Business Volume 2011 (grant & direct procurement)

GDF QUALITY ASSURANCE POLICY World Health Organization 14 October 2019 GDF QUALITY ASSURANCE POLICY Prequalification criteria for manufacturers and medicines: FPP is authorized by the relevant National Medicines Regulatory Authority (NMRA) in the country of use; AND Product is pre-qualified by WHO under the WHO PQP; OR Product is approved by an SRA; OR Product is found acceptable through a quality risk/benefit assessment process involving an Expert Review Panel (ERP). Time limited approval for 12 months pending WHO PQP or SRA approval This is reflected in the GDF QA policy implemented June 2010 and in full harmonisation with Global Fund QA policy http://www.stoptb.org/gdf/drugsupply/quality_sourcing_process.asp Established 2001 GDF/Stop TB Partnership/WHO 7

GDF DP Ordering Timelines TOTAL WITHIN GDF CONTROL: 3 - 6 MONTHS FROM DATE FUNDS RECEIVED Shipment (1-2 weeks air; 4-6 weeks sea) Pre shipment inspection & batch analysis (CRF) (4 weeks) Manufacturing (8-12 weeks if API is available, if not, add 4-12 weeks) GDF/PA place orders with manufacturers (1-2 weeks) Annual TB drug requirements quantified - unknown time frame NTP signs GDF procurement form/technical agreement for a request for quotation services- (average 2-3 weeks) Funding needs secured – unknown time frame GDF PROCUREMENT CYCLE ~8 MONTHS Lead times are most commonly misunderstood. In blue (right side) is what is out of GDF's control, and in green (left side) is what is in GDF's control. Moving clockwise: quantification, securing funding, requesting quotations is on the initiative of the NTP. Where most bottlenecks occur is in the signing of contracts and payments to procurement agent, which can take up to 2 months. NTP signs PA contract and payment is made (average 2 months) TOTAL WITHIN NTP/PR & DONOR CONTROL: ESTIMATE MINIMUM 5 MONTHS

Request for Quotation: Challenges Buffer stock & Shelf life: GDF recommends calculating a buffer stock in consideration of shelf life of products (most 1st line products have 24 months exp.); if 100% buffer is requested: stagger deliveries (every 6 months). Cost efficiency: limit air freight to no more than 20% of total order. Quotations are only valid for 90 days FLD and 60 days SDL: Client should clarify any outstanding questions on their PSM plan with the FPM prior to a request for quotation. This is will save weeks in quotation revisions.

Manufacturing: Challenges No stockpile available for 1st line drugs (fresh production takes 8-12 weeks); Strategic Rotating Stockpile available for certain 2nd line drugs for emergencies API not always available, especially for Rifampicin Batch requirements for paediatric drugs (manufacturers will wait until they receive enough orders for minimum batch quantities before production in started) API: Active Pharmaceutical Ingredient

GDF 1st Line anti-TB Drug Grants In 2011, GDF saw a sharp increase in requests for 1st line emergency grants: 24 approved 2010 vs 42 approved in 2011. In 2012, already 27 grants approved. Increase in demand commonly due to: late signing of new GF grants, PSM plan approvals, delay of Phase II signing, GF grant discontinued, or national funding not enough to cover needs or just not available.

2nd line anti-TB Patient treatments supplied by GDF, by WHO regions (data June 14, 2012)

GDF Diagnostics Old New New Diagnostics Expand TB Project "Narrowing the Gap: Expanding and accelerating access to diagnostics for patients at risk of MDR-TB" Project Partners GLI, GDF, FIND Operating in 27 countries (23 MOUs signed) 120,000 MDR-TB cases to be detected 87.5 million US$ budget -> Procurement of Liquid Culture and Line Probe Assay equipment via GDF Direct Procurement mechanism Gene Xpert (Cepheid Inc.) TB REACH Initiative 190 machines, 349,000 cartridges delivered 29 projects in 24 countries ~10 million US$ Standard Diagnostics · ~5 million US$ GDF Diagnostics New Diagnostics Old New Microscope Kit LED Microscope Equipment Starter Kit Equipment and Starter Kit Consumables Kit Diagnostics and Consumables Kit Sputum Container Kit

Technical Assistance in Drug Management GDF Monitoring Missions: quantification of annual needs & identification of further TA needs (44 missions in 2011 & ~65 missions in 2012); currently this is free of charge to direct procurement clients; reports shared with the FPMs Further in-country TA support will need to be paid for from GF/donor budget Regional Support Officers being recruited for AFRO and EMRO (Q4 2012) RSOs to provide individualized assistance to countries in order calculation and placement and in-country drug management training

Conclusion: GDF Added Value Pooled procurement: GDF is able to aggregate demand for anti-TB products for more timely & simplified procurement. Pricing: GDF conducts international bidding regularly in order to achieve competitive, transparent pricing. Quantification & Forecasting: GDF assists countries in identifying their drug needs and when they need them. Quality assurance policy aligned with the Global Fund Technical Assistance & monitoring: periodic monitoring of GDF clients and identification of their PSM challenges.